MarketCapExport financials
Harvard Bioscience (HBIO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Harvard Bioscience Financial Ratios 2025-2008 | HBIO
Brief overview of Harvard Bioscience's financial ratios
The review covers five available annual periods spanning 2009 to 2014.
The valuation comparison uses P/E 71.17x (median 45.6x), EV/EBITDA 73.64x (median 36.92x), P/S 0.24x (median 0.96x). Current valuation broadly matches recent historical reference points; the difference from five-year medians is 0%.
The 1/P/E calculation produces a 1.4% earnings yield. It does not capture future growth or capital structure.
Capital efficiency is characterized by ROE -4.1%, ROA -70.8%, ROCE -3.5%. The business is not generating positive returns on invested resources. Valuation should be read cautiously until earnings recover.
The cash conversion cycle lengthened from 199.5 days to 242.6 days, or 43 days. More cash is tied up in operations.
Conclusion
Harvard Bioscience's market valuation is near its own historical norm, while quality ratios provide no extreme signal.
Annual Financial Ratios Harvard Bioscience
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.4 | -1.6 | -55.0 | -11.5 | -756.4 | -23.0 | -24.1 | -41.8 | -188.8 | -23.0 | -5.2 | 71.2 | -75.0 | 45.6 | 23.0 | 40.1 | 102.6 | - |
P/S |
0.2 | 0.2 | 1.7 | 1.0 | 1.8 | 1.8 | 1.0 | 1.0 | 1.6 | 0.9 | 0.9 | 1.5 | 1.3 | 1.0 | 0.8 | 7.0 | 8.6 | - |
EPS |
-1.3 | -0.3 | -0.1 | -0.2 | -0.0 | -0.2 | -0.1 | -0.1 | -0.0 | -0.1 | -0.6 | 0.1 | -0.1 | 0.1 | 0.1 | 0.7 | 0.2 | - |
EV (Enterprise Value) |
78.6 M | 79.7 M | 248 M | 178 M | 289 M | 251 M | 188 M | 200 M | 187 M | 129 M | 136 M | 194 M | 153 M | 117 M | 101 M | 777 M | 725 M | -13.7 M |
EBITDA per Share |
-1.06 | -0.1 | 0.08 | -0.13 | 0.1 | 0.153 | 0.201 | 0.175 | 0.0674 | 0.0464 | 0.0564 | 0.293 | 0.207 | 0.216 | 0.327 | 0.49 | 0.31 | - |
EV/EBITDA |
-1.7 | -17.8 | 73.6 | -32.5 | 70.9 | 36.9 | 20.9 | 27.4 | 72.3 | 67.7 | 59.1 | 18.6 | 21.7 | 16.1 | 9.3 | 55.0 | 78.3 | - |
PEG |
-0.01 | 0.01 | 0.63 | 0.5 | -23.49 | -0.32 | -0.72 | -0.12 | 2.23 | 0.3 | 0.01 | -0.32 | 0.43 | -1.18 | -0.29 | - | - | - |
P/B |
1.5 | 0.3 | 2.6 | 1.5 | 2.6 | 2.3 | 1.4 | 1.5 | 2.0 | 1.4 | 1.3 | 1.8 | 1.5 | 1.0 | 0.9 | 8.4 | - | - |
P/CF |
3.1 | 14.2 | 13.4 | 94.9 | 172.6 | 21.9 | 16.6 | 65.0 | 1276.1 | 25.4 | -43.9 | 71.4 | 57.7 | 17.3 | 17.0 | 62.0 | 44.9 | - |
ROE % |
-412.84 | -19.58 | -4.67 | -13.18 | -0.35 | -10.19 | -5.74 | -3.53 | -1.07 | -5.97 | -24.54 | 2.47 | -1.94 | 2.27 | 3.99 | 21.07 | 9.61 | - |
ROA % |
-70.81 | -9.80 | -2.49 | -6.55 | -0.18 | -5.00 | -2.84 | -1.73 | -0.79 | -4.00 | -15.84 | 1.73 | -1.35 | 1.78 | 3.01 | 15.24 | - | - |
ROCE % |
-353.72 | -9.81 | 2.59 | -9.60 | 2.48 | 0.16 | 1.32 | 0.67 | -0.11 | -1.22 | -0.92 | 5.80 | 3.09 | 2.81 | 5.59 | 11.32 | 10.70 | - |
Current Ratio |
1.2 | 2.0 | 2.1 | 2.0 | 2.1 | 2.5 | 2.1 | 2.7 | 3.4 | 3.1 | 2.6 | 3.2 | 3.8 | 6.0 | 6.0 | 3.6 | - | - |
DSO |
65.2 | 60.0 | 53.3 | 62.1 | 60.8 | 63.5 | 65.0 | 74.3 | 73.3 | 69.6 | 71.9 | 70.1 | 61.3 | 62.3 | 58.9 | 26.0 | - | - |
DIO |
219.4 | 222.3 | 202.2 | 187.7 | 177.5 | 184.4 | 155.3 | 159.0 | 143.6 | 129.8 | 136.1 | 126.3 | 100.2 | 110.3 | 113.1 | 51.3 | - | - |
DPO |
42.0 | 47.9 | 47.4 | 39.5 | 38.8 | 49.5 | 37.6 | 46.6 | 36.3 | 40.3 | 53.5 | 38.7 | 29.7 | 29.1 | 30.9 | 15.9 | - | - |
Operating Cycle |
284.6 | 282.4 | 255.5 | 249.8 | 238.3 | 247.9 | 220.3 | 233.3 | 216.8 | 199.4 | 208.0 | 196.5 | 161.5 | 172.6 | 172.0 | 77.3 | - | - |
Cash Conversion Cycle |
242.6 | 234.4 | 208.1 | 210.3 | 199.5 | 198.5 | 182.8 | 186.6 | 180.5 | 159.1 | 154.5 | 157.7 | 131.7 | 143.6 | 141.2 | 61.4 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Harvard Bioscience
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.52 | -0.77 | - | -0.03 | -0.05 | -1.14 | - | -0.11 | -0.07 | -0.11 | - | -0.03 | -0.02 | 0.01 | - | -0.08 | 0.06 | -0.17 | - | - | -0.01 | -0.02 | - | -0.03 | -0.04 | -0.12 | 0.02 | -0.07 | -0.01 | -0.06 | 0.08 | -0.01 | -0.04 | -0.11 | 0.03 | -0.01 | -0.01 | -0.03 | -0.04 | -0.05 | -0.02 | -0.02 | -0.51 | -0.02 | 0.01 | -0.04 | - | 0.02 | 0.03 | 0.03 | -0.02 | -0.03 | -0.01 | - | 0.04 | -0.01 | 0.02 | 0.02 | 0.03 | - | 0.05 | 0.06 |
EBITDA per Share |
0.08 | -0.16 | - | 0.02 | 0.01 | -1.12 | - | -0.01 | -0.02 | -0.04 | - | 0.01 | 0.05 | 0.05 | - | -0.05 | 0.13 | -0.15 | - | 49.2 | 37.9 | 0.01 | - | 42 | 40 | -0.07 | 0.04 | - | 0.03 | 0.01 | 0.05 | 0.06 | 0.02 | -0.02 | 0.01 | 0.02 | 0.01 | - | -0.03 | 0.01 | - | - | - | 0.01 | 0.03 | -0.02 | 0.07 | 0.07 | 0.07 | 0.07 | -0.03 | 0.05 | 0.05 | 0.06 | 0.07 | 0.07 | 0.11 | 0.08 | 0.05 | 0.04 | 0.11 | 0.08 |
ROE % |
-60.94 | -396.67 | -362.59 | -369.94 | -365.54 | -357.86 | -18.53 | -20.19 | -14.14 | -8.95 | -2.13 | -6.86 | -2.05 | -9.76 | -10.60 | -10.82 | -6.61 | -10.62 | -1.61 | -3.04 | -4.88 | -10.25 | -9.38 | -8.71 | -10.48 | -8.73 | -5.74 | -2.95 | -0.05 | -1.52 | -3.53 | -5.76 | -5.96 | -4.66 | -1.07 | -4.13 | -5.89 | -6.40 | -5.97 | -26.23 | -25.05 | -23.61 | -24.54 | -2.47 | -0.71 | -0.09 | 2.78 | 2.00 | 0.30 | -0.95 | -1.92 | 0.04 | 0.95 | 1.87 | 2.27 | 1.90 | 2.05 | 2.74 | 0.77 | 0.03 | 1.43 | - |
ROA % |
-11.67 | -71.90 | -67.51 | -71.17 | -71.86 | -72.54 | -9.45 | -10.34 | -7.37 | -4.67 | -1.15 | -5.50 | -4.72 | -4.30 | -4.73 | -4.73 | -4.73 | -5.17 | -0.82 | -1.52 | -2.42 | -5.05 | -4.60 | -4.27 | -5.16 | -4.30 | -2.84 | -1.48 | -0.04 | -0.76 | -1.73 | -2.52 | -2.75 | -2.23 | -0.79 | -2.93 | -4.07 | -4.38 | -4.00 | -17.05 | -16.23 | -15.28 | -15.86 | -1.60 | -0.42 | 0.04 | 1.96 | 1.41 | 0.22 | -0.66 | -1.34 | 0.12 | 0.74 | 1.45 | 1.78 | 1.46 | 1.58 | 2.08 | 0.58 | 0.02 | 1.08 | - |
ROCE % |
-16.78 | -350.29 | -338.61 | -341.48 | -345.95 | -344.06 | -9.26 | -10.51 | -6.59 | -1.16 | 2.15 | -3.07 | 3.34 | -6.50 | -8.86 | -8.14 | -2.84 | -8.31 | 0.48 | 0.71 | 0.73 | -3.62 | -3.31 | -1.31 | -3.22 | -3.66 | 0.46 | 0.57 | 3.31 | 2.57 | 1.19 | -0.45 | -2.01 | -1.88 | -0.78 | -2.80 | -3.45 | -4.28 | -4.15 | -2.45 | -2.32 | -1.03 | -2.21 | -0.13 | 2.36 | 4.05 | 7.36 | 4.13 | 3.07 | 1.96 | 1.55 | 4.60 | 5.27 | 6.94 | 7.51 | 6.92 | 6.04 | 6.30 | 1.45 | 0.23 | 2.64 | - |
Current Ratio |
1.2 | 1.1 | 2.0 | 1.2 | 1.2 | 1.2 | 2.0 | 2.0 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.0 | 2.0 | - | - | 1.9 | 2.1 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 2.0 | 3.8 | 3.8 | 3.8 | 3.8 | 3.0 | 3.0 | 3.0 | 3.0 | 2.8 | 2.8 | 2.8 | 2.8 | 3.4 | 3.4 | 3.4 | 3.4 | 3.3 | 3.3 | 3.6 | 3.3 | 4.6 | 4.6 | 4.6 | 4.6 | 4.1 | 4.1 | 4.1 | - |
DSO |
68.3 | 64.7 | - | 53.3 | 56.7 | 59.4 | - | 52.6 | 54.9 | 58.5 | - | 57.4 | 55.0 | 52.4 | - | - | 31.7 | 66.8 | - | 55.0 | 53.9 | 58.9 | - | 67.4 | 69.5 | 73.8 | 61.0 | 68.9 | 63.9 | 68.2 | 57.8 | 68.4 | 62.1 | 59.4 | 56.4 | 65.2 | 64.4 | 73.5 | 54.4 | 57.5 | 55.0 | 56.3 | 56.4 | 62.2 | 55.6 | 59.7 | 48.5 | 57.9 | 54.6 | 50.8 | 45.5 | 50.3 | 48.5 | 49.4 | 46.4 | 50.2 | 46.0 | 47.4 | 47.4 | 52.1 | 25.3 | - |
DIO |
220.1 | 243.6 | - | 233.5 | 230.6 | 219.1 | - | 253.4 | 227.5 | 228.8 | - | 222.7 | 199.9 | 209.1 | - | - | 104.2 | 203.8 | - | 173.2 | 168.3 | 177.4 | - | 192.7 | 214.9 | 187.4 | 146.5 | 161.8 | 147.7 | 178.6 | 151.4 | 178.6 | 141.6 | 141.8 | 144.7 | 166.8 | 155.5 | 197.3 | 127.2 | 136.7 | 125.9 | 137.7 | 132.0 | 145.6 | 125.8 | 136.9 | 113.5 | 133.8 | 127.6 | 112.8 | 91.1 | 112.2 | 110.9 | 110.7 | 109.1 | 114.7 | 108.8 | 109.7 | 104.9 | 114.3 | 57.7 | - |
DPO |
45.7 | 54.0 | - | 52.7 | 48.8 | 45.6 | - | 54.5 | 54.3 | 54.3 | - | 47.1 | 40.4 | 48.8 | - | - | 22.6 | 40.3 | - | 44.8 | 49.4 | 48.9 | - | 51.7 | 57.6 | 47.8 | 35.5 | 39.2 | 35.8 | 48.1 | 44.4 | 52.4 | 41.5 | 39.8 | 37.9 | 43.7 | 40.7 | 56.9 | 39.5 | 42.5 | 39.1 | 48.8 | 51.9 | 57.2 | 49.5 | 48.1 | 34.8 | 41.0 | 39.1 | 34.1 | 27.0 | 31.5 | 31.1 | 30.9 | 28.8 | 30.2 | 28.7 | 29.4 | 28.6 | 31.2 | 15.8 | - |
Operating Cycle |
- | - | - | 286.8 | 287.3 | 278.5 | - | 306.0 | 282.4 | 287.3 | - | 280.0 | 254.8 | 261.5 | - | - | 135.9 | 270.6 | - | 228.1 | 222.2 | 236.3 | - | 260.1 | 284.5 | 261.3 | 207.5 | 230.8 | 211.6 | 246.8 | 209.3 | 247.0 | 203.7 | 201.2 | 201.1 | 232.0 | 219.9 | 270.8 | 181.6 | 194.2 | 180.9 | 194.0 | 188.4 | 207.8 | 181.4 | 196.6 | 162.1 | 191.6 | 182.3 | 163.7 | 136.6 | 162.5 | 159.3 | 160.1 | 155.5 | 164.8 | 154.7 | 157.1 | 152.3 | 166.4 | 83.0 | - |
Cash Conversion Cycle |
- | - | - | 234.1 | 238.6 | 232.9 | - | 251.5 | 228.2 | 233.0 | - | 232.9 | 214.5 | 212.8 | - | - | 113.3 | 230.3 | - | 183.3 | 172.8 | 187.4 | - | 208.4 | 226.8 | 213.4 | 172.1 | 191.6 | 175.8 | 198.7 | 164.8 | 194.6 | 162.2 | 161.4 | 163.2 | 188.4 | 179.2 | 213.9 | 142.1 | 151.7 | 141.8 | 145.3 | 136.6 | 150.6 | 132.0 | 148.4 | 127.2 | 150.6 | 143.1 | 129.6 | 109.5 | 131.0 | 128.2 | 129.2 | 126.7 | 134.6 | 126.1 | 127.7 | 123.6 | 135.2 | 67.3 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Harvard Bioscience, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Glaukos Corporation
GKOS
|
$ 167.89 | 1.44 % | $ 9.6 B |  USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
AngioDynamics
ANGO
|
$ 11.05 | 1.38 % | $ 459 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 121.11 | 0.67 % | $ 5.71 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 13.6 | 0.74 % | $ 281 M | USA |
 |
iRhythm Technologies
IRTC
|
$ 106.05 | 0.97 % | $ 3.39 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 420.24 | 0.52 % | $ 150 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.11 | 3.67 % | $ 144 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 82.62 | 1.31 % | $ 1.87 B | USA |
 |
Milestone Scientific
MLSS
|
$ 0.34 | 1.34 % | $ 27.9 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 87.16 | 0.18 % | $ 5.16 B | USA |
 |
Nephros
NEPH
|
$ 3.52 | 0.56 % | $ 37.4 M | USA |
 |
Envista Holdings Corporation
NVST
|
$ 22.82 | 0.75 % | $ 3.83 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 46.32 | 7.66 % | $ 3.12 B | USA |
 |
ICU Medical
ICUI
|
$ 162.69 | 0.09 % | $ 4.01 B | USA |
 |
Pro-Dex
PDEX
|
$ 59.82 | 0.04 % | $ 193 B | USA |
 |
Repligen Corporation
RGEN
|
$ 178.2 | 1.58 % | $ 10 M | USA |
 |
ResMed
RMD
|
$ 235.29 | 0.11 % | $ 34.2 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.59 | 0.8 % | $ 17.7 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 21.84 | 1.58 % | $ 1.08 B | USA |
 |
STERIS plc
STE
|
$ 217.26 | 0.64 % | $ 21.3 B | USA |
 |
Stereotaxis
STXS
|
$ 1.05 | 2.7 % | $ 95.5 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 123.29 | 0.35 % | $ 5.5 B | USA |
 |
Utah Medical Products
UTMD
|
$ 74.79 | 0.11 % | $ 242 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.71 | 0.51 % | $ 273 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 374.65 | 0.77 % | $ 27.1 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 8.44 | 0.29 % | $ 1.68 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
The Cooper Companies
COO
|
$ 54.88 | 0.53 % | $ 10.9 B | USA |
 |
Microbot Medical
MBOT
|
$ 0.99 | 0.49 % | $ 45.3 M |  Israel |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
$ 38.61 | 3.51 % | $ 1.84 B | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Alcon
ALC
|
$ 63.87 | 1.38 % | $ 31.5 B |  Schweiz |
 |
Becton, Dickinson and Company
BDX
|
$ 188.89 | 0.81 % | $ 54.3 B | USA |
 |
AtriCure
ATRC
|
$ 57.3 | 0.76 % | $ 2.74 B | USA |
 |
Baxter International
BAX
|
$ 24.8 | 0.46 % | $ 12.7 B | USA |
 |
electroCore
ECOR
|
$ 8.2 | 0.06 % | $ 69.6 K | USA |